Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Modified beac as bridging/lymphodepletion therapy followed by CAR-T and autologous stem cell support in relapsed or refractory DLBCL patients: Insights from safety and efficacy outcomes in 12 patients

View Full Paper
Ask AI
Bookmark
Share

Authors

TYTao YouHHHaiwen Huang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved progression-free survival and manageable adverse events after CAR-T therapy in DLBCL patients.

Key Points

  • Neutropenia and cytopenias were the most common adverse events following the modified BEAC regimen.
  • The study observed a high overall response rate of 91.7%, indicating effective targeted therapy in relapsed DLBCL patients.
  • Analysis of survival outcomes revealed a progression-free survival rate of 91.7% at the median follow-up of 9.3 months.
  • Carmustine and etoposide were key components of the modified BEAC regimen used for lymphodepletion during therapy.

Cite This Study

You et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df50https://doi.org/10.1182/blood-2025-3719
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma2025
  2. 2CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.2026
  3. 3Feasibility, outcomes and challenges of CAR-T cell therapy as advanced or earlier line of treatment for B-cell non-Hodgkin lymphomas: A multicenter national study2025
  4. 4Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025
  5. 5Recent trends in the management of relapsing/refractory diffuse large B-cell lymphoma: A systematic review of the literature2025